ProLynx LLC

20 patents currently held · Updated Nov 14, 2026

1 more in force is now held by another company

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Ending by 2030

Aug 2029

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Jan 9, 2027
The maintenance fee for Slow-release conjugates of SN-38 (US 10,342,792) comes due Jan 9, 2027. Unpaid by Jul 9, 2027, it lapses early.
1 fee due Feb 22, 2027
The maintenance fee for Synergistic cancer treatment (US 11,730,836) comes due Feb 22, 2027. Unpaid by Aug 23, 2027, it lapses early.
1 fee due Mar 3, 2027
The maintenance fee for Hydrogels with biodegradable crosslinking (US 10,398,779) comes due Mar 3, 2027. Unpaid by Sep 3, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

1 of the patents on this record was granted since Aug 16, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Patent	Title	Status	Expires	Confidence
US 9,387,254	Prodrugs and drug-macromolecule conjugates having controlled drug release rates In force Term ends Aug 1, 2029 · From the USPTO record	In force	Term ends Aug 1, 2029	From the USPTO record
US 8,680,315	Prodrugs and drug-macromolecule conjugates having controlled drug release rates In force Term ends Oct 27, 2030 · From the USPTO record	In force	Term ends Oct 27, 2030	From the USPTO record
US 8,703,907	Controlled drug release from dendrimers In force Term ends May 5, 2031 · From the USPTO record	In force	Term ends May 5, 2031	From the USPTO record
US 8,754,190	Controlled release from macromolecular conjugates In force Term ends May 5, 2031 · From the USPTO record	In force	Term ends May 5, 2031	From the USPTO record
US 8,946,405	Controlled release from solid supports In force Term ends Oct 25, 2031 · From the USPTO record	In force	Term ends Oct 25, 2031	From the USPTO record
US 11,179,470	Hydrogels with biodegradable crosslinking In force Ends no later than Sep 7, 2032 · From the USPTO record	In force	Ends no later than Sep 7, 2032	From the USPTO record
US 11,181,803	Hydrogels with biodegradable crosslinking In force Ends no later than Sep 7, 2032 · From the USPTO record	In force	Ends no later than Sep 7, 2032	From the USPTO record
US 11,454,861	Hydrogels with biodegradable crosslinking In force Ends no later than Sep 7, 2032 · From the USPTO record	In force	Ends no later than Sep 7, 2032	From the USPTO record
US 9,649,385	Hydrogels with biodegradable crosslinking In force Term ends Sep 25, 2032 · From the USPTO record	In force	Term ends Sep 25, 2032	From the USPTO record
US 10,398,779	Hydrogels with biodegradable crosslinking In force Term ends Nov 1, 2032 · From the USPTO record	In force	Term ends Nov 1, 2032	From the USPTO record

10 of 20 patents shown.

Pro members see all 20.

Pro members: see all 20 patents

Also on record, not counted in the 20: 1 patent in force now held by others. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

2 pending · 7 no status recorded

List them